Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
irradiated MMC10-AD whole tumor cell vaccine
- Development stage
- Preclinical
- Lead developer
- Cleveland Clinic
- Modality
- Vaccines & Immunotherapeutics, Cell Therapies
- Administration
- Subcutaneous, Intradermal
01
Overview
irradiated MMC10-AD whole tumor cell vaccine is an experimental, preclinical whole-cell cancer vaccine derived from the MMC10-AD mouse mammary carcinoma cell line. The MMC10-AD cell line is established by culturing spontaneous breast tumor cells from Her-2/neu transgenic mice in standard, adherent (AD) serum-containing conditions. The vaccine consists of these cells after they have been lethally irradiated. In preclinical research, it is utilized to study immune tolerance and evaluate the priming of CD4+ and CD8+ neu-reactive T cells, often serving as a comparative control to vaccines derived from breast cancer stem-like cells (MMC10-BCSC).
- Other names
- irradiated MMC10-AD vaccineirradiated MMC10-AD whole cell vaccine
Beyond the preview
Go deeper on irradiated MMC10-AD whole tumor cell vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on irradiated MMC10-AD whole tumor cell vaccine.